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Abstract
IMPORTANCE—Over ⅔ of U.S. women are overweight or obese, placing them at increased risk 
for postmenopausal breast cancer.
OBJECTIVE—To investigate the associations of overweight and obesity with risk of 
postmenopausal invasive breast cancer after extended follow-up in the Women’s Health Initiative 
(WHI) Clinical Trial.
DESIGN—The WHI protocol incorporated measured height and weight, baseline and annual or 
biennial mammography, and adjudicated breast cancer endpoints.
SETTING—40 U.S. clinical centers.
PARTICIPANTS—n=67,142 postmenopausal women aged 50–79 years were enrolled from 
1993–1998 with a median of 13 years of follow-up through 2010; 3388 invasive breast cancers 
were observed.
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MAIN OUTCOMES AND MEASURES—Height and weight were measured at baseline and 
weight was measured annually thereafter. Data were collected on demographic characteristics, 
personal and family medical history and personal habits (smoking, physical activity). Women 
underwent annual or biennial mammograms. Breast cancers were verified by medical records 
reviewed by physician adjudicators.
RESULTS—Women who were overweight and obese had an increased invasive breast cancer risk 
vs. normal weight women. Risk was greatest for obesity grades 2+3 (BMI>35.0 kg/m2) (hazard 
ratio [HR] for invasive breast cancer =1.58, 95% CI 1.40–1.79). BMI ≥ 35.0 kg/m2 was strongly 
associated with risk for ER+/PR+ breast cancers (HR=1.86 95% CI 1.60–2.17), but was not 
associated with ER− cancers. Obesity grade 2+3 was also associated with advanced disease 
including larger tumor size (HR=2.12 95%CI 1.67–2.69). (P=0.02), positive lymph nodes 
(HR=1.89 95%CI 1.46–2.45), (P=0.06), regional/distant stage (HR=1.94, 95%CI 1.52–2.47) 
(P=0.05) and deaths after breast cancer (HR=2.11 95%CI 1.57–2.84) (P<0.001). Women with 
baseline BMI<25.0 kg/m2 who gained >5% of bodyweight over the follow-up period had an 
increased breast cancer risk (HR=1.36 95% CI 1.1–1.65), but among women already overweight 
or obese we found no association of weight change (gain or loss) with breast cancer during follow-
up. There was no effect modification of the BMI-breast cancer relationship by postmenopausal 
hormone therapy (HT) and the direction of association across BMI categories was similar for 
never, past and current HT use.
CONCLUSIONS/RELEVANCE—Obesity is associated with increased invasive breast cancer 
risk in postmenopausal women. These clinically meaningful findings should motivate programs 
for obesity prevention.
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INTRODUCTION
Obesity is a major public health problem in the United States. Recent data demonstrate that 
the age-adjusted obesity (BMI ≥ 30.0 kg/m2) prevalence is 34.9% among all adults age 20 
years and older while that for overweight plus obesity (BMI ≥ 25.0 kg/m2) is 68.5%.1 
Obesity has been associated with breast cancer risk in observational studies,2,3 systematic 
reviews and meta-analyses.3–5 More recently, the 2012 Annual Report to the Nation on 
Cancer6 concluded that overweight and obese women have a relative risk for 
postmenopausal breast cancer of 1.13 and 1.25, respectively vs. normal weight women.
Despite relatively strong and consistent evidence that obesity may increase postmenopausal 
breast cancer risk, questions remain, including whether obesity is associated with breast 
cancer characteristics, such as tumor hormone receptor status and stage at diagnosis or 
whether use of postmenopausal hormone therapy (HT) modifies the obesity-breast cancer 
association, since both obesity and HT alter a woman’s hormone profile. Questions also 
remain regarding any interaction of race/ethnicity and obesity and breast cancer risk. Black 
women in the United States have higher rates of obesity1 and lower breast cancer rates, but 
higher mortality, than non-Hispanic white women.4 Here we examine the associations of 
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overweight and obesity with postmenopausal breast cancer risk in the Women’s Health 
Initiative Clinical Trials (WHI CT)7,8 where the protocol requirements specified baseline 
and annual or semi-annual mammograms and measured weights.
METHODS
Design details of the three overlapping WHI CTs have been published.7 Briefly, women 
aged 50–79 years were recruited at 40 U.S. clinical centers from 1993–1998. Women could 
be randomized to one, two or all three CTs (one of two hormone trials and trials of dietary 
modification and calcium and vitamin D supplementation). Eligibility criteria included being 
postmenopausal and anticipated three years survival. Exclusions included prior breast 
cancer, other prior cancer (except non-melanoma skin cancer) within 10 years, and 
conditions related to adherence and safety. Trial protocols were reviewed and approved by 
the Institutional Review Boards at each clinical center and the Clinical Coordinating Center. 
All women signed informed consent. Re-consents were required to continue follow-up 
through the post-trial WHI Extension periods (2005–10 and 2011–16).
For the HT trials, women with an intact uterus (n=16,608) were randomized to oral 
conjugated equine estrogen (CEE) (0.625 mg/d) plus medroxyprogesterone acetate (MPA) 
(Prempro®) (2.5 mg/d) or placebo. Women with a prior hysterectomy (n=10,739) were 
randomized to oral CEE (0.625 mg/d) (Premarin®) or placebo. Dietary modification (DM) 
trial participants were randomized to an intervention (n=19,541) to reduce fat intake and 
increase fruit, vegetable and grain consumption or a comparison group (n=29,294). After 
one year, women could participate in the calcium plus vitamin D (CaD) trial, with 
randomization to a daily dose of vitamin D3 (400 IU) and calcium (1000 mg) or placebo.
Height, weight, waist circumference and hip circumference were measured at baseline and 
weight was measured at annual visits. Body mass index (BMI) was computed as weight(kg)/
height(meters)2 and further defined as normal weight (BMI<25.0 kg/m2), overweight (25–
<30 kg/m2), obese-grade I (30–<35 kg/m2) and obese-grades 2+3 (≥ 35 kg/m2).1 Weight 
change (%) was defined as [(annual visit weight – baseline weight)]/baseline weight × 100]. 
Baseline data were collected on demographic characteristics, smoking, alcohol, physical 
activity, medical history and family history of breast cancer. Mammograms and clinical 
breast exams were required at baseline and annually for women in the HT trials and baseline 
and biennially in the DM trial. Baseline serum sex hormone levels were available on 200 
randomly selected HT participants.9
Details of outcomes data collection, adjudication and primary trial results have been 
published.10–15 Women were queried about new medical events every six months during the 
intervention and annually thereafter. Breast cancers and breast cancer characteristics (tumor 
hormone receptor status, histology, stage, grade, tumor size, nodal involvement) were 
verified by medical records and pathology report review by physician adjudicators using the 
National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) coding 
system. Vital status was collected through follow-up of participants and proxies and periodic 
searches of the National Death Index. Cause of death was determined by medical record and 
death certificate review.
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Associations between obesity and breast cancer incidence and mortality are presented as 
hazard ratios [HR] and 95% confidence intervals [CI] from Cox models using event times 
measured as time from randomization. The proportional hazards assumption for the primary 
analysis was verified by Schoenfeld residuals (p > 0.38), and by visual inspection of linear 
time-varying coefficients. All analyses were stratified by baseline 5-year age groups, WHI 
randomization assignment(s), hysterectomy status, and study phase (intervention vs. post-
intervention) and adjusted for age (continuous), race/ethnicity, education, parity, age at first 
birth, bilateral oophorectomy, family history of breast cancer, prior estrogen use and 
duration, prior estrogen plus progestin use and duration, smoking, diabetes, and alcohol 
consumption. Since mammography use was required by the WHI protocol and compliance 
was good,7,8 no additional adjustment for mammography use was applied. Breast cancer 
mortality data were collected as deaths attributed to breast cancer and as all deaths after 
breast cancer. Trend tests were computed using BMI categories as a continuous variable. 
When examining different breast cancer characteristics,16 heterogeneity in BMI trends was 
tested using competing risk methods. Graphical representation of the shape of the relative 
risk relationship across BMI categories was created by fitting nonparametric splines to the 
multivariable adjusted hazard ratios in R, version 2.15.3 (R Core Team, 2013, R Foundation, 
Vienna Austria).
Associations of weight change with breast cancer risk were examined with similar Cox 
regression models stratified by baseline BMI category and using a time-dependent weight 
change variable updated with annual weight measurements and displayed in five categories: 
weight stable (± 2% of baseline weight), 2%–5% weight gain, >5% weight gain, 2%–5% 
weight loss, or >5% weight loss. The trend test was based on these weight change categories 
and the test for heterogeneity in trends between baseline BMI category was based on 
interaction tests.
The relationship between BMI and breast cancer incidence within HT use subgroups was 
examined using similar approaches and the P-values were based on interaction tests. HT 
subgroups were determined compositely by baseline self-report of HT and randomization 
into the WHI HT trials. Specifically, participants randomized to HT were categorized as 
“current”; participants with no prior HT use were categorized as “never”; and all others were 
categorized as “past.” Lastly, participants not randomized in the HT trial were categorized 
per their baseline HT use. In exploratory analyses, nonparametric fits (spline) of the 
multivariable association between invasive breast cancer risk and BMI were examined; 
smoothing parameter was chosen objectively via Akaike information criteria (AIC). Similar 
analyses also examined the nonparametric risk of weight and included height as a covariate. 
Unless otherwise noted, all analyses were conducted in SAS version 9.3 (Cary, NC) and 
were not adjusted for multiple testing. Women with baseline weight (> 135 or < 35 kg) or 
BMI (> 50.0 or < 18.5 kg/m2) measurements were excluded; 67,142 of 68,132 participants 
and 3388 breast cancers were included in this study. See also eMethods in the Supplement.
Neuhouser et al. Page 4














Participant characteristics differed by baseline BMI category (Table 1). Obese women were 
likely to be younger, non-White, less educated, have had a hysterectomy or bilateral 
oophorectomy, been treated for diabetes, less likely to have used HT and report less 
recreational physical activity compared to normal weight women.
Women who were overweight, obese-grade 1 and obese-grades 2+3 had an increased 
invasive breast cancer risk relative to normal weight women (Table 2). The hazard ratios 
increased as BMI increased and displayed a dose-response effect with the greatest risk for 
women with grades 2+3 obesity (HR= 1.58 95%CI 1.40–1.79, P-trend <0.001). Tests of 
heterogeneity suggested that the association between BMI and breast cancer risk differed by 
hormone receptor status (P< 0.001). BMI was associated with an increased risk of ER+PR+ 
breast cancer and the hazard ratios increased at each BMI level suggesting a dose-response 
relationship (HR = 1.86, 95% CI 1.60–2.17 for BMI ≥ 35 kg/m2). In exploratory analyses, 
measures of central adiposity (waist circumference and waist-to-hip ratio) were added to the 
multivariable adjusted model of weight. Neither measure of central adiposity conferred any 
additional information (P > 0.40) beyond what was already explained by weight (data not 
shown).
Obesity was associated with more advanced disease including larger tumor size (P=0.02), 
positive lymph nodes (P = 0.06) and regional/distant stage at diagnosis (P= 0.05) (Table 2 
and eFigure 1 in the Supplement). BMI was strongly associated with breast cancer mortality 
only for obesity grades 2+3 (HR=2.25, 95% CI 1.51–3.36) (P<0.001) and mortality after 
invasive breast cancer for all obesity grades (grade 1 HR = 1.35 95% CI 1.04–1.79 and 
grades 2+3 HR=2.11 95% CI 1.57–2.84) (P<0.001).
Women who gained > 5% of their baseline weight during follow-up had a modest increased 
risk (HR=1.12 95% CI 1.00–1.25, P-trend = 0.08) compared to weight stable women, but 
there was no change in risk for women who lost weight (Table 3). Subgroup analyses 
suggested that associations between weight change and breast cancer risk was modified by 
baseline BMI (P-interaction = 0.05). Women with normal BMI who gained > 5% of their 
body weight during follow-up increased their breast cancer risk, relative to weight stable 
women (HR=1.36 85% CI 1.11–1.65), but neither weight gain nor loss further changed risk 
for overweight and obese women.
A priori subgroup analyses investigated whether associations of BMI with invasive breast 
cancer risk varied by age, race/ethnicity and HT (Table 4 and eFigure 2). Baseline age 
modified the association of BMI with cancer risk such that the associations appeared slightly 
weaker among the youngest women (P-interaction=0.05), but the overall obesity-breast 
cancer risk relationship remained strong. There was no evidence of effect modification of the 
BMI-invasive breast cancer relationship by race/ethnicity (P-interaction =0.34). Among 
women with an intact uterus, use of E+P did not modify the association of BMI with cancer 
risk as the data support a similar trend between BMI and breast cancer risk across the E+P 
use categories (P-interaction = 0.78). Among women with a prior hysterectomy, data were 
suggestive, but not conclusive, of an interaction between E-alone and BMI in relation to 
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breast cancer risk (P-interaction=0.11). In particular, a low incidence rate for the referent 
normal weight group (annualized percentage = 0.23%) among women who never used E-
alone was associated with linear, dose-response risk estimates for overweight (HR=1.66, 
95% CI 1.06–2.60), obesity-grade I (HR=2.16 95% CI 1.38–3.39) and obesity-grades 2+3 
(HR=2.63, 95% CI 1.32–2.00). For the subgroup defined as “current use” of E-alone the 
BMI-associated risk was increased only for current E-alone users who were obese-grade I 
(HR=1.35 95% CI 1.07–1.71) or obese-grades 2+3 (HR = 1.47 95% CI 1.12–1.92). A post-
hoc analysis that contrasted subgroups defined by never used E-alone and ever used E-alone 
(past or current) was more suggestive of effect modification; HR(95%CI) of 1.01 (0.83, 
1.22), 1.28 (1.04, 1.58), 1.44 (1.14, 1.83) among women who ever used E-alone for 
overweight, obese-grade I, and obese-grades 2+3, respectively (P-interaction=0.04). In a 
sensitivity analysis differentiating between prior E+P or E-alone use among the post-
hysterectomy group, a similar association was observed between BMI and breast cancer 
among women who never used E-alone or E+P. Specifically, HRs (95%CI) were 1.65 (1.02, 
2.68), 2.30 (1.42, 3.73), and 2.80 (1.70, 4.60) for overweight, obese-grade 1 and obese 
grades 2+3, respectively.
We next examined whether the interpretation of results varied by the type of obesity measure 
used: BMI or, weight including height as a covariate. The multivariable-adjusted risk for the 
BMI-invasive breast cancer association was mostly linear for the vast majority (middle 90%) 
of the distribution (eFigure 3a) and plateaued near 40 kg/m2; the 5th and 95th percentiles 
were 21.3 kg/m2 and 39.3 kg/m2, respectively. However, the multivariable-adjusted risk 
associated with weight (kg) was non-linear (eFigure 3b) even among the middle 90% of 
participants; the 5th and 95th percentiles were 54.5 kg and 104.5 kg, respectively.
To better understand the shapes of the curves for the BMI and weight models where the 
breast cancer rates increase with both measures, but attenuated at the highest BMI levels 
(eFigures 3a, 3b), we explored the relationship between the sex hormones and BMI. 
Smoothed estimates of baseline mean estradiol, estrone and SHBG in the available subset of 
participants (n=200) were plotted against BMI (Figure 1). Estradiol had a linear relationship 
with BMI, but the association between estrone and BMI dampens for grades 2+3 obesity. 
Lastly, the sharp decrease observed between mean serum SHBG concentrations and 
increasing BMI levels-off for grades 2+3 obesity.
DISCUSSION
The Women’s Health Initiative Clinical Trial examined the association of overweight and 
obesity with invasive breast cancer risk in postmenopausal women. Unlike many 
observational studies, weight, height and body circumferences were measured at baseline 
and annually using a standardized protocol throughout the trial, annual or biennial 
mammography was a required trial protocol element thus minimizing ascertainment bias, 
and breast cancer outcomes (including details on breast cancer characteristics: tumor 
hormone receptor status, histology, nodal involvement, tumor grade and disease stage) were 
adjudicated by physician adjudicators. In this context, BMI was positively associated with 
increased risk of invasive breast cancer (P<0.001). We observed a strong linear trend where 
the risk progressively increased across the BMI categories. The strongest associations were 
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observed for women with a BMI >35 kg/m2; these women had a 58% increased risk of 
invasive breast cancer compared to women with BMI <25.0 kg/m2. Breast cancer deaths 
were also more than two-fold higher among grade 2+3 obesity compared to normal BMI.
Obesity was associated with breast cancer characteristics including tumor size, lymph node 
positivity and regional/distant stage at diagnosis. In addition, women with ER+/PR+ tumors 
who were obese-grade I or obese-grades 2+3 had 52% and 86% increased risk of breast 
cancer, respectively, compared to women of normal BMI. The growth of ER+ tumors are 
under estrogen influence17,18 and estrogen levels are higher in overweight and obese 
postmenopausal women due to the aromatization of androstendione and testosterone to 
estrogens in adipose tissue.19,20 Further, obese individuals have larger and more abundant 
adipose tissue cells than normal weight individuals and these women typically have greater 
endogenous synthesis of estrogens in their adipose tissue. Leptin may also increase estrogen 
levels21 and while we have no available leptin data, leptin is higher in overweight and obese 
individuals than in normal weight individuals.22,23 These biological relationships of BMI 
and altered hormone and cytokine profiles and the potential causal relationships with breast 
cancer risk are supported by our data showing a strong linear relationship between baseline 
BMI and both estradiol and estrone and are consistent with a previous report on the role of 
serum hormone and breast carcinogenesis.24
The WHI CT results differ from findings in the National Surgical Adjuvant Breast and 
Bowel Project Breast Cancer Prevention Trial (NSABP P-1) and the Study of Tamoxifen and 
Raloxifene (STAR).2526–28 In contrast to the findings reported here in the WHI CT, the P-1 
and STAR results showed a modest, but non-significant, increased risk for postmenopausal 
breast cancer (RR= 1.14, 95% CI 0.94–1.38) for women with a BMI ≥ 30.0 kg/m2 compared 
to women with a BMI < 25.0 kg/m2.25 Similar to the WHI CT, the NSABP trials had 
baseline breast cancer risk assessment, baseline and serial mammography, and adjudicated 
breast cancer outcomes. However, the NSABP results are not directly comparable to those 
reported here because nearly 75% of NSABP participants were randomized to tamoxifen or 
raloxifene, agents that decrease breast cancer incidence by almost 50%.26–28 As a result, 
there were fewer than 3,200 postmenopausal women who were randomized to placebo 
where findings could reasonably be compared to those in the WHI CT. The HRs for breast 
cancer risk in obese-grade I and obese-grades 2+3 NSABP postmenopausal-placebo 
participants were 1.77 and 1.28, respectively, P=0.36. However, the limited sample size 
precludes reliable generation of information regarding BMI influence on breast cancer risk 
in women not receiving these effective chemoprevention agents.
Several observational studies have reported that the relationship between obesity and breast 
cancer risk is modified by postmenopausal HT use.29–32 Huang found that higher vs. lower 
BMI was associated with an increased postmenopausal breast cancer risk (RR=1.59 95% CI 
1.09–2.32, P-trend <0.001), except among current and past HT users.30 Subsequent 
observational studies from the Carolina Breast Cancer Study,31 a follow-up analysis from 
the Nurses’ Health Study,29 the Breast Cancer Surveillance Consortium,32 the WHI 
Observational Study33 and others34–37 have similarly reported apparent effect modification 
of the obesity-breast cancer relationship by HT use. Many investigators reporting 
interactions of HT and obesity in relation to breast cancer risk have posited that HT use 
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obscures the effects of obesity, particularly in relation to their effects on circulating hormone 
levels. To our knowledge a biological mechanism to explain these associations has not been 
identified nor have results been confirmed with evidence from randomized clinical trials. Of 
note, two previous reports from the WHI clinical trials38,39 did not find an interaction 
between BMI and CEE-alone or CEE+MPA and in this report we found no effect 
modification and similar directions of associations were observed across BMI categories for 
never, past and current HT use. While we did find attenuations of the risk estimates for ever-
users of estrogen-alone among women with a prior hysterectomy, the association between 
obesity and breast cancer remained. Differences in findings may be due to observational 
studies’ reliance on self-reported height and weight, self-reported HT, and may be subject to 
mammography screening and ascertainment bias when outcomes are collected by self-
report. Notably, there are higher rates of routine screening mammograms for women 
receiving postmenopausal HT; the larger detection rates from screening mammograms could 
introduce bias in the observational studies if obese women underwent screening 
mammography at a different rate than normal weight women.40
The WHI findings of consistent dose-response risks across the BMI categories regardless of 
postmenopausal HT use have clinical implications. One report32 suggested that since the 
obesity-breast cancer risk was attenuated or not observed among HT users, obese women 
may benefit from HT use as they observed no excess breast cancer risk for these women. 
However, the preponderance of evidence suggests that postmenopausal HT is not beneficial 
for multiple health outcomes, including breast cancer, and the risks outweigh the benefits.41
One intriguing finding was that WHI women who began the study at BMI<25.0 kg/m2 and 
gained >5% of body weight over the follow-up period had a breast cancer HR=1.36 (95%CI 
1.1, 1.65) compared to weight stable women. After menopause the breast tissue evolves 
toward a higher adipose content. Breast tissue adipocytes serve as a source of inflammatory 
cytokines as well as local estrogen production.19,20 It is possible that a weight gain-induced 
sudden and steep rise in breast adipocytes and exposure to cytokines and estrogens could 
explain why normal weight women who gain >5% bodyweight had an increased risk for 
breast cancer compared to weight stable women. These results suggest that prevention of 
weight gain may be an important public health strategy for reducing breast cancer risk.
In contrast, women who were overweight or obese at baseline had no change in risk by 
weight gain or loss during follow-up relative to weight stability. It is important to note that 
the WHI CT was not a weight loss trial and the weight change data we present may reflect 
both intentional and unintentional weight loss. Well-designed clinical trials are needed to 
definitively test whether weight loss and body composition changes in overweight and obese 
women or obesity prevention in normal weight women will reduce breast cancer risk. In 
addition, it is not clear at what stage in life excess weight confers the greatest risk. For 
example, during adolescence and pregnancy, breast epithelial cells undergo rapid division 
and differentiation. It is possible that obesity superimposed on this rapid cell growth may set 
the stage for aberrant cell growth and biological susceptibility to breast cancer.5,42 Another 
susceptible timepoint may be the menopause when breast tissue is undergoing further 
changes.
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Strengths of this WHI-CT report include the large sample size, standardized data collection, 
adjudicated breast cancers, protocol-required mammography and limited loss to follow-up. 
Limitations include fewer race/ethnic minority participants, lack of data on tumor molecular 
characteristics,43 and fewer data on longer term weight and body composition changes and 
inability to distinguish from unintentional weight loss. Death from breast cancer was not 
common, so the elevated mortality risk for women with grade 2+3 obesity should be viewed 
with caution. Finally, we had insufficient power to examine risk for distant stage only due to 
very few cases presenting with distant stage at diagnosis.
In conclusion, obesity is associated with a dose-response increased postmenopausal breast 
cancer risk, particularly for ER+/PR+ disease, but risk does not vary by HT use or race/
ethnicity. These clinically meaningful findings support the need for trials clinical trials 
evaluating the role of obesity prevention and treatment on breast cancer risk.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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